Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Clinics in Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology. 2016; 64: 73-84
- Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2019; 4: 389-398
- Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol.J Clin Lipidol. 2016; 10: 420-425 e421
- Significant correlations between severe fatty liver and risk factors for metabolic syndrome.J Gastroenterol Hepatol. 2007; 22: 2118-2123
- New trends on obesity and NAFLD in Asia.J Hepatol. 2017; 67: 862-873
- A global survey of physicians knowledge about nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol. 2022; 20: e1456-e1468
- Advancing the global public health agenda for NAFLD: a consensus statement.Nat Rev Gastroenterol Hepatol. 2022; 19: 60-78
- The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.Hepatology. 2018; 67: 328-357
- From NASH to HCC: current concepts and future challenges.Nat Rev Gastroenterol Hepatol. 2019; 16: 411-428
- Influence of nonalcoholic fatty liver disease with increased liver enzyme levels on the risk of cirrhosis and hepatocellular carcinoma.Clin Gastroenterol Hepatol. 2022; S1542-3565: 00105-00107
- Prospective study of outcomes in adults with nonalcoholic fatty liver disease.N Engl J Med. 2021; 385: 1559-1569
- Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.Hepatology. 2022; 75: 1235-1246
- Non-alcoholic fatty liver disease - a global public health perspective.J Hepatol. 2019; 70: 531-544
- Disease progression of nonalcoholic steatohepatitis in Taiwanese patients: a longitudinal study of paired liver biopsies.Eur J Gastroenterol Hepatol. 2019; 31: 224-229
- Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.Clin Gastroenterol Hepatol. 2015; 13 (e641-649;quiz e639-640): 643-654
- Association of histologic disease activity with progression of nonalcoholic fatty liver disease.JAMA Netw Open. 2019; 2: e1912565
- Progression of fatty liver disease in children receiving standard of care lifestyle advice.Gastroenterology. 2020; 159: 1731-1751 e1710
- First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients.Hepatol Int. 2021; 15: 1136-1147
- Placebo effect on progression and regression in NASH: evidence from a meta-analysis.Hepatology. 2022; 75: 1647-1661
- On the value and limitations of liver histology in assessing non-alcoholic steatohepatitis.J Hepatol. 2020; 73: 1592-1593
- Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice.Expert Rev Mol Diagn. 2021; 21: 1065-1078
- Metabolically healthy obesity and the development of nonalcoholic fatty liver disease.Am J Gastroenterol. 2016; 111: 1133-1140
- Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs.Clin Med. 2007; 7: 119-124
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis.Hepatology. 2017; 65: 1557-1565
- The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH.Hepatology. 2019; 70: 1885-1888
- The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials.Hepatology. 2019; 70: 1913-1927
- Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography.Gut. 2012; 61: 409-415
- Decompensated cirrhosis is the commonest presentation for NAFLD patients undergoing liver transplant assessment.Clin Med. 2020; 20: 313-318
- Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.J Gastroenterol Hepatol. 2022; 37: 795-811
- Baveno VII - renewing consensus in portal hypertension.J Hepatol. 2022; 76: 959-974
- Optimizing use of nonalcoholic fatty liver disease fibrosis score, fibrosis-4 score, and liver stiffness measurement to identify patients with advanced fibrosis.Clin Gastroenterol Hepatol. 2019; 17: 2570-2580.e37
- Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease.Gut. 2019; 68: 2057-2064
- Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease.Am J Gastroenterol. 2021; 116: 723-732
- Baveno criteria safely identify patients with compensated advanced chronic liver disease who can avoid variceal screening endoscopy: a diagnostic test accuracy meta-analysis.Front Physiol. 2019; 10: 1028
- Effect of sarcopenia on survival in patients with cirrhosis: a meta-analysis.J Hepatol. 2022; 76: 588-599
- Sarcopenia from mechanism to diagnosis and treatment in liver disease.J Hepatol. 2016; 65: 1232-1244
- Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis.Gastroenterology. 2015; 149 (e365; quiz e314-365): 367-378
- A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis.N Engl J Med. 2021; 384: 1113-1124
- Once-weekly semaglutide in adults with overweight or obesity.N Engl J Med. 2021; 384: 989-1002
- NAFLD and liver transplantation: disease burden, current management and future challenges.JHEP Rep. 2020; 2: 100192
- Incidence and risks for nonalcoholic fatty liver disease and steatohepatitis post-liver transplant: systematic review and meta-analysis.Transplantation. 2019; 103: e345-e354
- The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015.JAMA Oncol. 2017; 3: 1683-1691
- Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.Hepatology. 2015; 62: 1723-1730
- NAFLD-associated HCC: progress and opportunities.J Hepatocell Carcinoma. 2021; 8: 223-239
- Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review.World J Hepatol. 2019; 11: 1-18
- Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2019; 30: 871-873
- Weighing the benefits of hepatocellular carcinoma surveillance against potential harms.J Hepatocell Carcinoma. 2019; 6: 23-30
- Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: current insights and advancements.World J Gastroenterol. 2021; 27: 3466-3482
- Pathomolecular characterization of HCC in non-cirrhotic livers.Hepatoma Res. 2020; 6: 47
- GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score.Cancer Epidemiol Biomarkers Prev. 2019; 28: 531-538
- GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis.Clin Gastroenterol Hepatol. 2020; 18: 728-735.e724
Roche - doing now what patients need next, Available at: https://www.roche.com/media/releases/med-cor-2020-03-04 Accessed January 05, 2023.
- Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.BMC Cancer. 2019; 19: 621
- Role of non-coding RNAs in liver disease progression to hepatocellular carcinoma.Arch Pharm Res (Seoul). 2019; 42: 48-62
- Progress and prospects of long noncoding RNAs (lncRNAs) in hepatocellular carcinoma.Cell Physiol Biochem. 2015; 36: 423-434
- Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma.Nat Mater. 2017; 16: 1155-1161
- Association between physical activity and risk of hepatobiliary cancers: a multinational cohort study.J Hepatol. 2019; 70: 885-892
- Mediterranean diet and hepatocellular carcinoma.J Hepatol. 2014; 60: 606-611
Article info
Publication history
Published online: March 09, 2023
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 Elsevier Inc. All rights reserved.
